Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

August 11, 2021

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

August 11, 2021

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

August 11, 2021

Antiandrogen agents, PARP inhibitors, and prostate-specific membrane antigen-directed therapy have broadened the armamentarium in prostate cancer.

August 10, 2021

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

August 10, 2021

Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.

August 10, 2021

The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.

August 09, 2021

Daniel C. Danila, MD, discusses the integration of advanced imaging in prostate cancer.

August 09, 2021

Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.

August 05, 2021

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

August 05, 2021

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

August 05, 2021

Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.

August 04, 2021

Anita Kumar, MD, discusses the improved efficacy of venetoclax when used in combination with ibrutinib compared with venetoclax or ibrutinib alone in mantle cell lymphoma. 

August 04, 2021

Chung-Han Lee, MD, PhD, discusses the goals of the phase 3 KEYNOTE-B61 study and the potential for immunotherapy/TKI combinations in non–clear cell RCC.

August 03, 2021

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

August 03, 2021

Anita Kumar, MD, discusses patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma.

August 03, 2021

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

August 03, 2021

Memorial Sloan Kettering Cancer Center, the world’s oldest and largest private cancer center, has launched MSKCC India to provide cancer patients in India with access to the institution’s world-renowned oncologists, research, clinical trials, and education.

July 31, 2021

Maria E. Arcila, MD, highlights important considerations for selecting among molecular diagnostic tests for patients with lung cancer.

July 28, 2021

Michael J. Morris, MD, discusses ongoing research efforts with 177Lu-PSMA-617 in prostate cancer.

July 27, 2021

Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.